LeMaitre Vascular (LMAT) & ViewRay (VRAY) Critical Survey
LeMaitre Vascular (NASDAQ: LMAT) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.
Insider and Institutional Ownership
66.3% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 53.7% of ViewRay shares are owned by institutional investors. 23.7% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 62.8% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares LeMaitre Vascular and ViewRay’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
LeMaitre Vascular has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, ViewRay has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500.
This is a breakdown of current recommendations for LeMaitre Vascular and ViewRay, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LeMaitre Vascular presently has a consensus target price of $28.60, indicating a potential downside of 25.87%. ViewRay has a consensus target price of $10.00, indicating a potential upside of 68.35%. Given ViewRay’s stronger consensus rating and higher probable upside, analysts plainly believe ViewRay is more favorable than LeMaitre Vascular.
LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.6%. ViewRay does not pay a dividend. LeMaitre Vascular pays out 31.9% of its earnings in the form of a dividend.
Earnings & Valuation
This table compares LeMaitre Vascular and ViewRay’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|LeMaitre Vascular||$96.40 million||7.61||$23.12 million||$0.69||55.91|
|ViewRay||$18.41 million||19.04||-$43.16 million||($1.29)||-4.60|
LeMaitre Vascular has higher revenue and earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
LeMaitre Vascular beats ViewRay on 9 of the 15 factors compared between the two stocks.
About LeMaitre Vascular
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.